Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.

Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.

OBJECTIVE:The aim of this study was to clarify whether serum matrix metalloproteinase 3 (MMP-3) levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA). METHODS:Forty three patients with RA were treated with igura...

Full description

Bibliographic Details
Main Authors: Nao Tokai, Shuzo Yoshida, Takuya Kotani, Ayaka Yoshikawa, Yuko Kimura, Youhei Fujiki, Yoko Matsumura, Tohru Takeuchi, Shigeki Makino, Shigeki Arawaka
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6107217?pdf=render

Internet

http://europepmc.org/articles/PMC6107217?pdf=render

Similar Items